2025
Molecular markers associated with survival in PD-L1– high non-small cell lung cancer treated with first-line immunotherapy versus chemoimmunotherapy.
Lee V, Oh P, Rybkin A, Patel A, Kim S, Park H. Molecular markers associated with survival in PD-L1– high non-small cell lung cancer treated with first-line immunotherapy versus chemoimmunotherapy. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e20607.Peer-Reviewed Original ResearchNon-small cell lung cancerFirst-line immunotherapyTreated with first-line immunotherapyPD-L1 expressionCell lung cancerPD-L1Advanced non-small cell lung cancerLung cancerPresence of co-mutationsAssociated with improved OSAssociated with worse OSBaseline ECOG performance statusMultivariate Cox proportional hazards modelSingle-agent immunotherapyUS cancer clinicsAdvanced NSCLC patientsECOG performance statusOptimal treatment strategyCox proportional hazards modelsAssociated with survivalClinico-genomic databasePresence of brainProportional hazards modelTreated with IMetastatic sites
2020
The role of targeted therapy (TKI) in the treatment of advanced hepatocellular carcinoma (aHCC) in the era of immunotherapy: Real-world data using AI analytics from an academic medical center.
Wong R, Wu J, Leen A, Tey G, Asokumaran Y, Chan G, Siddappan C, Jeyasekharan A, Chee C, Yong W, Ngiam K, Sundar R. The role of targeted therapy (TKI) in the treatment of advanced hepatocellular carcinoma (aHCC) in the era of immunotherapy: Real-world data using AI analytics from an academic medical center. Journal Of Clinical Oncology 2020, 38: e16623-e16623. DOI: 10.1200/jco.2020.38.15_suppl.e16623.Peer-Reviewed Original ResearchAdvanced hepatocellular carcinomaEra of immunotherapySequence of therapySystemic therapyOverall survivalHCC patientsClinical outcomesManagement of advanced hepatocellular carcinomaTreated with first-line immunotherapyTreatment of advanced hepatocellular carcinomaFirst-line immunotherapyFirst-line TKIsSecond-line immunotherapySecond-line TKIsLoco-regional therapiesProgression-free survivalSecond-line therapySecond-line treatmentPillar of treatmentChild-Pugh scoreMinority of patientsSecond-lineFirst-lineMedian ageTargeted therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply